Have a feature idea you'd love to see implemented?
Let us know!
CTMX CytomX Therapeutics Inc
Price (delayed)
$1.08
Market cap
$84.37M
P/E Ratio
7.71
Dividend/share
N/A
EPS
$0.14
Enterprise value
$51.95M
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics,
Highlights
CTMX's equity has surged by 63% year-on-year
CTMX's revenue has surged by 50% year-on-year
CytomX Therapeutics's net income has surged by 126% YoY but it has decreased by 33% QoQ
The EPS has soared by 122% YoY but it has contracted by 30% from the previous quarter
CTMX's quick ratio is down by 24% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of CTMX
Market
Valuations
Earnings
Shares outstanding
78.12M
Market cap
$84.37M
Enterprise value
$51.95M
Price to earnings (P/E)
7.71
Price to book (P/B)
N/A
Price to sales (P/S)
0.77
EV/EBIT
3.45
EV/EBITDA
2.49
EV/Sales
0.43
Revenue
$119.57M
EBIT
$15.08M
EBITDA
$20.88M
Free cash flow
-$86.29M
Per share
Balance sheet
Liquidity
EPS
$0.14
Free cash flow per share
-$1.02
Book value per share
-$0.4
Revenue per share
$1.41
TBVPS
$1.86
Total assets
$159.22M
Total liabilities
$190.45M
Debt
$11.75M
Equity
-$31.23M
Working capital
$222,000
Debt to equity
-0.38
Current ratio
1
Quick ratio
0.99
Net debt/EBITDA
-1.55
Margins
Efficiency
Dividend
EBITDA margin
17.5%
Gross margin
100%
Net margin
9.3%
Operating margin
4.8%
Return on assets
5.8%
Return on equity
N/A
Return on invested capital
64.8%
Return on capital employed
92.2%
Return on sales
12.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTMX stock price
How has the CytomX Therapeutics stock price performed over time
Intraday
0%
1 week
-6.9%
1 month
-9.24%
1 year
-14.96%
YTD
-30.32%
QTD
-8.47%
Financial performance
How have CytomX Therapeutics's revenue and profit performed over time
Revenue
$119.57M
Gross profit
$119.57M
Operating income
$5.72M
Net income
$11.09M
Gross margin
100%
Net margin
9.3%
CytomX Therapeutics's net income has surged by 126% YoY but it has decreased by 33% QoQ
CTMX's net margin has surged by 118% year-on-year but it is down by 33% since the previous quarter
The operating income has soared by 112% year-on-year but it has declined by 47% since the previous quarter
The company's operating margin has surged by 108% YoY but it fell by 47% QoQ
Growth
What is CytomX Therapeutics's growth rate over time
Valuation
What is CytomX Therapeutics stock price valuation
P/E
7.71
P/B
N/A
P/S
0.77
EV/EBIT
3.45
EV/EBITDA
2.49
EV/Sales
0.43
The EPS has soared by 122% YoY but it has contracted by 30% from the previous quarter
CTMX's equity has surged by 63% year-on-year
The stock's P/S is 86% less than its 5-year quarterly average of 5.5 and 36% less than its last 4 quarters average of 1.2
CTMX's revenue has surged by 50% year-on-year
Efficiency
How efficient is CytomX Therapeutics business performance
CTMX's return on assets has surged by 132% year-on-year but it is down by 28% since the previous quarter
The ROS has soared by 124% YoY but it has contracted by 27% from the previous quarter
The ROIC has soared by 112% YoY and by 2.9% QoQ
Dividends
What is CTMX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTMX.
Financial health
How did CytomX Therapeutics financials performed over time
CTMX's total assets is 16% less than its total liabilities
The company's total liabilities fell by 35% YoY and by 12% QoQ
The company's current ratio fell by 25% YoY and by 14% QoQ
CTMX's debt is 138% greater than its equity
The debt to equity has dropped by 171% year-on-year but it has increased by 7% since the previous quarter
CTMX's equity has surged by 63% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.